Investor Ideas #Potcasts; #Cannabis News
and Stocks on the Move; CSE: $SNN.C,
CSE: $HUGE.C, CSE: $PILL.C, TSXV: $OGI.V, CSE:
$HIKU.C, CSE: $MYM.C, OTC: $CBIS, CSE: $CALI.C
July 10th #Potcast
sponsored by Lexaria Bioscience ( CSE: $LXX.C ) (OTC: $LXRP) a #Cannabis
company with a new disruptive drug delivery platform: DehydraTECH
Pt. Roberts, WA; Delta, BC –July 10, 2018
(Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its “potcast’
site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the July 10th podcast:
Read
this in full at http://www.investorideas.com/news/2018/cannabis/07103Potcasts-CSE-SNN-HUGE-PILL-TSXV-OGI-HIKU-MYM-OTC-CBIS-CALI.asp
Today’s podcast overview/transcript:
Good morning and welcome to another Investorideas.com potcast; looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts.
Today’s potcast was sponsored by Kelowna based Lexaria Bioscience Corp trading on the CSE under symbol LXX and on
the OTC as LXRP. Lexaria has developed a new disruptive
drug delivery platform: DehydraTECH The Company’s patented technology changes
the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally:
1) Masks unwanted tastes – eliminates the need for sugar-filled edibles.
2) Reduces time of onset – effects are felt within 15-20 min vs. 60-120
min.
3) Avoids first-pass liver metabolism
4) Increases bio-absorption by 5-10X
The Company’s DehydraTECH™ technology is patent-protected for multiple
APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal
anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine and Fat soluble
vitamins.
Today’s podcast features news announcements
from Sunniva Inc ( CSE:SNN) , FSD
Pharma Inc. ( CSE:
HUGE and OTC as FSDDF) , Canntab Therapeutics Limited (
CSE:
PILL) ,
Organigram Holdings Inc. (TSX-VENTURE:OGI) , Hiku Brands Company Ltd ( CSE:HIKU) , MYM Nutraceuticals Inc ( CSE:MYM and
OTC: MYMMF) , Cannabis Science. (OTC:
CBIS ) and
FinCanna Capital Corp. (CSE:
CALI).
Sunniva
Inc., a North American provider of cannabis products and services, announced
that it intends to spin out its Canadian assets into a separate Canadian entity
and apply to list the shares on the Toronto Stock Exchange (“TSX”) and
the NASDAQ Stock Market (“NASDAQ”) in an effort to unlock the underlying
value of the Company’s assets on both sides of the border. The Company has
retained Canaccord Genuity Corp. to act as a financial advisor in connection
with the Spinout Transaction and other strategic initiatives.
The Company
expects the Spinoff Transaction will be completed prior to the end of 2018.
FSD Pharma Inc., which,
through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer
pursuant to the Access to Cannabis for
Medical Purposes Regulations, announced that it has entered into a
non-binding letter of intent with Canntab Therapeutics Limited (CSE: PILL), a
leader in the rapidly growing cannabis pill market. Under the terms of the LOI,
FSD Pharma will assist Canntab to obtain a license to process and sell cannabis
products pursuant to the Cannabis Act
and will provide Canntab with space at its 620,000 square foot facility, which
is located just one hour east of Toronto in Cobourg, Ontario.
FSD Pharma
will provide Canntab with up to 10,000 square feet of space at the FSD
Facility. Canntab will build and install, at its expense, its own manufacturing
facility within the larger FSD Facility that will operate in accordance with
Good Manufacturing Practices, at which it will produce a suite of novel
cannabis oral dose delivery platforms, including gel capsules and tablets, and
other types of cannabis-based products, including sleep aids and pain
relievers. FSD Pharma and Canntab see
tremendous opportunity in offering pharmaceutical quality cannabis based
tablets, as many doctors are averse to prescribing smoked cannabis as a
solution to patients' health concerns. The Canntab Premises are intended to be
used to supply Canadian and International markets such as Australia and
Germany, which legally allow cannabis. FSD Pharma will work with Canntab to
prepare the necessary items to submit an application from Canntab to Health
Canada to obtain the License, which will be attached to the Canntab Premises.
Organigram
Holdings Inc., the parent company of Organigram Inc., a leading licensed
producer of medical marijuana, announced that it has entered into a letter of
intent with Hiku Brands Company Ltd. (CSE: HIKU).
As an
approved supplier to Manitoba Liquor & Lotteries ("MBLL"),
Organigram will supply Hiku with up to 1,000 kg of premium cannabis products
per year for the term of the three-year agreement. Products include both dried
cannabis and cannabis oils, which will be sold through designated Tokyo Smoke
retail locations in Manitoba.
"Organigram
and Hiku share a deep commitment to exceptional quality and innovative
products," says Greg Engel, CEO, Organigram. "As we move towards a
legal, adult recreational use cannabis market, we are proud to be affiliated
with companies and brands with a clear and demonstrated focus on their
customers and a first-class customer experience."
MYM
Nutraceuticals Inc., announced that it has entered into an Investment Agreement
to acquire a 49% stake in Colombian cannabis company, Colombia Organica, that
currently holds a seed to sale license for low THC cannabis. This license
permits Colombia Organica to grow, produce and create cannabis derivatives to
be commercialized and / or exported. Further, Colombia Organica is in the
licensing process for the cultivation and production of high THC cannabis
extracts.
MYM and
Colombia Organica have plans to build a production facility near Medellin,
Colombia for the cultivation and processing of cannabis and cannabis products.
Currently, Colombia Organica is developing and registering seed strains with
the Colombian Agricultural Institute.
Cannabis
Science, Inc., a U.S. company specializing in the development of
cannabinoid-based medicines, announced the immediate launch of a new 40-acre
industrial hemp research and development project in Nevada. Cannabis Science,
American States University (ASU), FSO NAC / HRM Farms celebrate as the Lincoln
County, Nevada industrial hemp property has just been approved by the Nevada
Department of Agriculture Industrial Hemp Program. The Group will immediately
commence its industrial hemp research operations on the 40-acre Lincoln County,
Nevada property.
The Group
believes it can bring in one and quite possibly two harvests this
year. The primary purpose of the research initiative is to provide hands-on
University professional training in agricultural industrial hemp research and
development focused on creating pharmaceutical drugs targeting critical
ailments while furthering the Group’s other industrial targets such as
Alternate Biofuels, Construction, Clothing and Automobile Materials, and other
industries. The University programs aim to provide affordable quality education
to its students so as to achieve their career goals and excel in their chosen
professions.
FinCanna
Capital Corp. a royalty company for the U.S. licensed medical cannabis
industry, has executed an Expanded Royalty Agreement with Refined Resin
Technologies Inc. formerly known as Gram Co Holdings LLC, of Oakland,
California. Refined Resin is a cannabinoid research and refinery company that
provides B2B and B2C products and services to licensed dispensaries and
distributors in the medical cannabis supply chain.
FinCanna
will fund US$3 million in tranches to complete the original Royalty Agreement
transaction that was previously announced under a binding term sheet in
February 2018. In return, FinCanna will receive a tiered corporate
royalty, ranging from 14% to 5.0% of Refined
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and
out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria's technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Google Play Music, Stitcher and Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Ideas
Investorideas.com is
a meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Investorideas.com
cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the
Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com
, the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria
Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast
starting July 5 2018 more info http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment